Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas MacDonald

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
Sexually Transmitted Infections|June 24, 2024
Multiple risk factors for persistent HBV viraemia in an adult receiving nucleos/tide analogue therapySheila Lumley, Maeve Barlow, Khadija Said, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 30, 2026
Emergency Department Opt-Out Testing for Hepatitis B: A Two-Year UK Multicentre Evaluation of Outcomes Across Seven SitesJennifer J Plunkett, Basil Ahmad, Amy Teague, et al.
Plos One|May 13, 2014
Quantification assays for total and polyglutamine-expanded huntingtin proteinsDouglas Macdonald, Michela A Tessari, Ivette Boogaard, et al.
Human Molecular Genetics|June 19, 2018
Identification of distinct conformations associated with monomers and fibril assemblies of mutant huntingtinJan Ko, J Mario Isas, Adam Sabbaugh, et al.
The Journal of Clinical Investigation|September 22, 2012
Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progressionAndreas Weiss, Ulrike Träger, Edward J Wild, et al.
Journal of Hepatology|August 10, 2017
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countriesAna da Silva Filipe, Vattipally Sreenu, Joseph Hughes, et al.
Journal of Hepatology|January 18, 2018
Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'"Ana da Silva Filipe, Vattipally Sreenu, Joseph Hughes, et al.
Plos One|April 8, 2022
Development of mAb-based polyglutamine-dependent and polyglutamine length-independent huntingtin quantification assays with cross-site validationDavid F Fischer, Sipke Dijkstra, Kimberly Lo, et al.
Plos One|December 3, 2014
Polyglutamine- and temperature-dependent conformational rigidity in mutant huntingtin revealed by immunoassays and circular dichroism spectroscopyValentina Fodale, Natalie C Kegulian, Margherita Verani, et al.
Molecular Cancer Therapeutics|August 10, 2019
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <i>PD-1xLAG-3</i>-Knockin MiceElena Burova, Aynur Hermann, Jie Dai, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
Sexually Transmitted Infections|June 24, 2024
Multiple risk factors for persistent HBV viraemia in an adult receiving nucleos/tide analogue therapySheila Lumley, Maeve Barlow, Khadija Said, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 30, 2026
Emergency Department Opt-Out Testing for Hepatitis B: A Two-Year UK Multicentre Evaluation of Outcomes Across Seven SitesJennifer J Plunkett, Basil Ahmad, Amy Teague, et al.
Plos One|May 13, 2014
Quantification assays for total and polyglutamine-expanded huntingtin proteinsDouglas Macdonald, Michela A Tessari, Ivette Boogaard, et al.
Human Molecular Genetics|June 19, 2018
Identification of distinct conformations associated with monomers and fibril assemblies of mutant huntingtinJan Ko, J Mario Isas, Adam Sabbaugh, et al.
The Journal of Clinical Investigation|September 22, 2012
Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progressionAndreas Weiss, Ulrike Träger, Edward J Wild, et al.
Journal of Hepatology|August 10, 2017
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countriesAna da Silva Filipe, Vattipally Sreenu, Joseph Hughes, et al.
Journal of Hepatology|January 18, 2018
Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'"Ana da Silva Filipe, Vattipally Sreenu, Joseph Hughes, et al.
Plos One|April 8, 2022
Development of mAb-based polyglutamine-dependent and polyglutamine length-independent huntingtin quantification assays with cross-site validationDavid F Fischer, Sipke Dijkstra, Kimberly Lo, et al.
Plos One|December 3, 2014
Polyglutamine- and temperature-dependent conformational rigidity in mutant huntingtin revealed by immunoassays and circular dichroism spectroscopyValentina Fodale, Natalie C Kegulian, Margherita Verani, et al.
Molecular Cancer Therapeutics|August 10, 2019
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <i>PD-1xLAG-3</i>-Knockin MiceElena Burova, Aynur Hermann, Jie Dai, et al.
Pageof 9